Phanes Therapeutics
Clinical trials sponsored by Phanes Therapeutics, explained in plain language.
-
New antibody drug targets Hard-to-Treat neuroendocrine cancers
Disease control Recruiting nowThis study tests a new drug, peluntamig (PT217), in people with advanced neuroendocrine cancers like small cell lung cancer. The drug is designed to attach to two proteins (DLL3 and CD47) found on cancer cells, potentially helping the immune system attack them. The trial will fir…
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called Spevatamig (PT886) in people with advanced stomach, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The drug is a type of antibody that targets two proteins on cancer cells to help the immune system attack them…
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …
Phase: PHASE1, PHASE2 • Sponsor: Phanes Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC